D
Keros Therapeutics, Inc. KROS
$15.03 $0.2651.80% NASDAQ
Recommendation
Prev Close
$14.76
Volume
316,066
Avg Vol (90D)
636,238
Market Cap
$599.48M
Dividend & Yield
--
52-Week Range
$9.12 - $72.37
P/E (TTM)
--
EPS (TTM)
-$1.10
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Stonepine Capital Management LLC Buys New Holdings in Keros Therapeutics, Inc. $KROS
8/26/2025 - MarketBeat
22NW LP Purchases Shares of 179,000 Keros Therapeutics, Inc. $KROS
8/26/2025 - MarketBeat
Keros Therapeutics (KROS, $14.76) RSI Indicator left the overbought zone on August 25, 2025
8/26/2025 - Tickeron - Stocks
Keros Therapeutics, Inc. (NASDAQ:KROS) Receives Consensus Rating of "Moderate Buy" from Brokerages
8/26/2025 - MarketBeat
Keros Therapeutics (KROS, $15.56) price may drop as it broke higher Bollinger Band on Aug 22, 2025
8/23/2025 - Tickeron - Stocks
Keros Therapeutics (KROS, $15.56) RSI Indicator left the overbought zone on August 22, 2025
8/23/2025 - Tickeron - Stocks
Keros Therapeutics (KROS, $15.17) entered Uptrend as Momentum indicator ascends above 0 level on Aug 21, 2025
8/22/2025 - Tickeron - Stocks
Keros Therapeutics: Orphan Drug Win For DMD Candidate A Small Step On Right Path
8/21/2025 - SeekingAlpha
ADAR1 Capital sends letter to Keros Therapeutics urging board changes
8/21/2025 - TipRanks Financial Blog
ADAR1 Capital sends letter to Keros Therapeutics urging board changes
8/21/2025 - The Fly
ADAR1 Sends Open Letter to Keros Board of Directors Urging the Board to Engage Constructively on Strategy, Capital Allocation and Board Refreshment
8/21/2025 - PR Newswire
Keros Therapeutics (KROS, $14.23) entered Downtrend as Momentum indicator drops below 0 level on Aug 20, 2025
8/21/2025 - Tickeron - Stocks
Keros Therapeutics Gains FDA Orphan Drug Designation
8/20/2025 - TipRanks Financial Blog
Keros Therapeutics granted Orphan Drug designation for KER-065 in DMD
8/20/2025 - The Fly
Keros Announces U.S. FDA Orphan Drug Designation Granted to KER-065 for the Treatment of Duchenne Muscular Dystrophy
8/20/2025 - Globe Newswire
Keros Therapeutics (KROS, $14.49) entered Uptrend as Momentum indicator ascends above 0 level on Aug 19, 2025
8/20/2025 - Tickeron - Stocks
Keros Therapeutics (KROS, $14.52) entered Downtrend as Momentum indicator drops below 0 level on Aug 18, 2025
8/19/2025 - Tickeron - Technical Analysis
Keros Therapeutics' treatment of Duchenne MD granted FDA orphan designation
8/18/2025 - TipRanks Financial Blog
Keros Therapeutics' treatment of Duchenne MD granted FDA orphan designation
8/18/2025 - The Fly
Keros Therapeutics (KROS, $14.48) Moving Average Convergence Divergence (MACD) Histogram turned positive on August 15, 2025
8/16/2025 - Tickeron - Stocks
Keros Therapeutics (KROS, $14.42) entered Uptrend as Momentum indicator ascends above 0 level on Aug 14, 2025
8/15/2025 - Tickeron - Stocks
Keros Therapeutics (KROS, $14.42) price moved above its 50-day Moving Average on August 14, 2025
8/15/2025 - Tickeron - Stocks
Notable Thursday Option Activity: KROS, LUNR, KVUE
8/14/2025 - Stock Options Channel
Keros Therapeutics Reports Strong Revenue Growth
8/14/2025 - TipRanks Financial Blog
Leerink Partnrs Has Negative Estimate for KROS Q3 Earnings
8/11/2025 - MarketBeat
Income Statement
Total Revenue (TTM)
$232.84M
EBITDA (TTM)
$1.67M
EBIT (TTM)
$312.00K
Net Income (TTM)
$18.77M
Balance Sheet
Total Assets (Q)
$757.17M
Total Debt (Q)
$17.95M
Total Liabilities (Q)
$50.43M
Book Value Per Share (Q)
$17.40
Cash Flow
Cash from Operations (TTM)
$55.04M
Cash from Investing (TTM)
-$1.96M
Cash from Financing (TTM)
$231.51M
Net Change in Cash (TTM)
$284.59M
Filings
Filing Date
Wednesday, August 6, 2025
Period Date
Monday, June 30, 2025
Next Filing
Week of Nov 3 and 7 (est)
Price History
Loading...
Beta
1.13
7-Day Total Return
3.76%
30-Day Total Return
5.44%
60-Day Total Return
6.18%
90-Day Total Return
11.05%
Year to Date Total Return
-5.62%
1-Year Total Return
-66.91%
2-Year Total Return
-57.81%
3-Year Total Return
-58.67%
5-Year Total Return
-71.95%
52-week Low
Apr 09, 2025 - $9.12
52-week High
Dec 09, 2024 - $72.37
Valuation
Market Cap
$599.48M - Small Cap
Enterprise Value
-$72.78M
Price/Sales (TTM)
2.57
Price/Book (Q)
0.85
Dividends and Shares
Shares Outstanding
40.61
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.kerostx.com
Phone Number
617 314 6297
Address
1050 Waltham Street
Lexington, MA 02421
Country
United States
Year Founded
2015
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the... more
NASDAQ 08/26/2025 1:20PM Eastern Quotes delayed